| scholarly article | Q13442814 |
| P50 | author | Larisa Gubareva | Q66732793 |
| Alexander I Klimov | Q104774724 | ||
| Vasiliy P Mishin | Q104774731 | ||
| P2093 | author name string | Ha T Nguyen | |
| Tiffany G Sheu | |||
| P2860 | cites work | Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States | Q45118572 |
| Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir | Q45742771 | ||
| Human influenza A viruses isolated in South America: genetic relations, adamantane resistance and vaccine strain match | Q46191150 | ||
| Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States | Q46925884 | ||
| Studies on fetuin, a glycoprotein of fetal serum. I. Isolation, chemical composition, and physiochemical properties. | Q47956010 | ||
| Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. | Q53449602 | ||
| The thiobarbituric acid assay of sialic acids | Q78734458 | ||
| Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action | Q27867721 | ||
| Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern | Q28275022 | ||
| Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants | Q28364114 | ||
| A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens | Q28830491 | ||
| Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans | Q29619059 | ||
| Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay | Q30308218 | ||
| Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. | Q30356751 | ||
| Zanamivir-resistant influenza viruses with a novel neuraminidase mutation | Q30379353 | ||
| Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. | Q30383771 | ||
| Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts | Q30387332 | ||
| Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. | Q30445738 | ||
| Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. | Q30452889 | ||
| Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. | Q30453005 | ||
| Neuraminidase inhibitors as anti-influenza virus agents | Q33730159 | ||
| Position statement: global neuraminidase inhibitor susceptibility network | Q34294358 | ||
| Influenza virus neuraminidase: structure, antibodies, and inhibitors | Q34318113 | ||
| Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide | Q34637724 | ||
| Influenzavirus neuraminidase and neuraminidase-inhibition test procedures | Q36786074 | ||
| Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. | Q36870919 | ||
| Influenza virus susceptibility and resistance to oseltamivir. | Q36974609 | ||
| Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season | Q37164761 | ||
| Structure of the complex oligosaccharides of fetuin | Q39528563 | ||
| Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir | Q39671211 | ||
| Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa | Q39973215 | ||
| Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate | Q41720424 | ||
| Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir | Q43210983 | ||
| Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. | Q43288467 | ||
| Drug resistance among influenza A viruses isolated in Italy from 2000 to 2005: are the emergence of Adamantane-resistant viruses cause of concern? | Q43561307 | ||
| Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons | Q44910895 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pandemic | Q12184 |
| P304 | page(s) | 3671-3677 | |
| P577 | publication date | 2010-06-28 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays | |
| P478 | volume | 54 |
| Q30410899 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives |
| Q30218773 | Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011. |
| Q27013442 | Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors |
| Q37263328 | Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens |
| Q35794372 | Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China |
| Q26782746 | Clinical Implications of Antiviral Resistance in Influenza |
| Q64134362 | Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa |
| Q30364319 | Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. |
| Q57010547 | Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors |
| Q30377552 | Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013 |
| Q38161553 | Detection and management of antiviral resistance for influenza viruses |
| Q30234600 | Drug resistance in influenza A virus: the epidemiology and management |
| Q34292717 | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
| Q30396031 | Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir |
| Q40152886 | Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial |
| Q36785817 | Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice |
| Q38804059 | Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? |
| Q90287155 | Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance |
| Q38088381 | Improving influenza virus detection |
| Q52602393 | Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. |
| Q37949284 | Influenza neuraminidase: a druggable target for natural products |
| Q64950730 | Influenza viruses - antiviral therapy and resistance. |
| Q42110576 | Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers |
| Q40369515 | Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. |
| Q30396669 | Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza |
| Q36584392 | Microevolution of highly pathogenic avian influenza A(H5N1) viruses isolated from humans, Egypt, 2007-2011. |
| Q30400621 | Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. |
| Q30404038 | Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. |
| Q45947329 | Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. |
| Q30408105 | Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective |
| Q30355297 | New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion |
| Q30404485 | Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis |
| Q35806412 | Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route |
| Q30412554 | Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. |
| Q30413154 | Peramivir for the treatment of influenza |
| Q28068310 | Peramivir injection in the treatment of acute influenza: a review of the literature |
| Q30429450 | Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations |
| Q30426630 | Recent progress and challenges in the discovery of new neuraminidase inhibitors |
| Q28076140 | Reverse Genetics Approaches for the Development of Influenza Vaccines |
| Q30353217 | Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study |
| Q35099847 | Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden |
| Q30397216 | The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients |
| Q36301052 | Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents |
| Q30202859 | Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses |
Search more.